Having shown last week that its opioid alternative can reduce post-surgery pain, Tris Pharma is back with another slice of ...

This week, the FDA will decide whether to approve Vertex Pharmaceuticals' non-opioid painkiller. Vertex believes pain could ...

The opioid crisis has touched nearly every demographic in our society. One area that doesn’t get enough attention is the toll ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Non-white communities had significantly less access to opioid medications commonly prescribed for moderate to severe pain than white communities over ...

From unexpected gender disparities to alarming teen statistics, discover essential facts about opioid medications that every ...

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a leading biotechnology company specializing in cystic fibrosis (CF) treatments, has been making significant strides in expanding its therapeutic portfolio ...

Through life experiences and relationships, it’s hard not to cross paths with people who’ve been impacted by the opioid ...

At the heart of Dogwood Therapeutics’ business model is its innovative work in pain relief. The company is a development-stage biopharmaceutical company with a specific focus on advancing non-opioid ...

Passing the Alternatives to PAIN Act would be an excellent way for Trump to uphold his promise to “Make America Healthy Again ...

The agreement also ends the Sacklers’ control of Purdue Pharma and prohibits them from selling opioids in the United States.

Several US states have reached a $7.4 billion settlement with the Sackler family and their pharmaceutical company Purdue over the opioid crisis that has ravaged the lives of millions of Americans, ...